

1 (1) in subparagraph (D)—

2 (A) in clause (ii), by striking “; and” and
3 inserting a semicolon;

4 (B) by redesignating clause (iii) as clause
5 (v); and

6 (C) by inserting after clause (ii) the fol-
7 lowing:

8 “(iii) the identification and develop-
9 ment of platform manufacturing tech-
10 nologies needed for advanced development
11 and manufacturing of medical counter-
12 measures for viral families which have sig-
13 nificant potential to cause a pandemic;

14 “(iv) advanced research and develop-
15 ment of flexible medical countermeasures
16 against priority respiratory virus families
17 and other respiratory viral pathogens with
18 a significant potential to cause a pandemic,
19 with both pathogen-specific and pathogen-
20 agnostic approaches; and”;

21 (2) in subparagraph (F)—

22 (A) in clause (ii), by striking “; and” at
23 the end and inserting a semicolon;

24 (B) in clause (iii), by striking the period
25 and inserting “; and”; and

1 (C) by adding at the end the following:

2 “(iv) priority virus families and other
3 viral pathogens with a significant potential
4 to cause a pandemic.”.

5 (b) FUNDING.—Section 319L(d)(2) of the Public
6 Health Service Act (42 U.S.C. 247d–7e(d)(2)) is amend-
7 ed—

8 (1) by striking “To carry out” and inserting
9 the following:

10 “(i) IN GENERAL.—To carry out”;

11 and

12 (2) by adding at the end the following:

13 “(ii) ADDITIONAL FUNDING.—In addi-
14 tion to the amounts appropriated under
15 clause (i), there is authorized to be appro-
16 priated to the Fund \$40,000,000 for each
17 of fiscal years 2024 through 2028, which
18 amounts shall be used solely for purposes
19 of carrying out clauses (iii) and (iv) of sub-
20 section (e)(4)(D), such amounts to remain
21 available until expended.”.